Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Poseida Therapeutics, Inc. | Chief Financial Officer | Common Stock | 246K | $1.02M | $4.13 | Mar 1, 2024 | Direct |
Poseida Therapeutics, Inc. | Chief Financial Officer | Employee Stock Option (Right to Buy) | 112K | Mar 1, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
PSTX | Poseida Therapeutics, Inc. | Mar 1, 2024 | 3 | -$74.7K | 4 | Mar 4, 2024 | Chief Financial Officer |
PSTX | Poseida Therapeutics, Inc. | Mar 1, 2023 | 3 | -$23.1K | 4 | Mar 2, 2023 | Chief Financial Officer |
PSTX | Poseida Therapeutics, Inc. | Mar 1, 2022 | 2 | $0 | 4 | Mar 1, 2022 | Chief Financial Officer |
PSTX | Poseida Therapeutics, Inc. | Dec 21, 2021 | 4 | $9.06K | 4 | Dec 22, 2021 | Chief Financial Officer |
PSTX | Poseida Therapeutics, Inc. | Nov 1, 2021 | 1 | $0 | 4 | Nov 2, 2021 | Chief Financial Officer |